https://www.selleckchem.com/pr....oducts/simufilam.htm
The aim of this study was to evaluate the effect of liraglutide treatment on glucose variability and the risk of hypoglycemia by continuous glucose monitoring (CGM) in persons with type 2 diabetes (T2D) and dialysis-dependent end-stage renal disease (ESRD). We assessed CGM data from a previous trial where 24 persons with T2D and dialysis-dependent ESRD were allocated (11) to 12 weeks of double-blinded treatment with liraglutide (titrated to maximum tolerable dose up to 1.8 mg) or placebo as an add-on to preexisting antidiabetic treatm
Like
Comment
Share
